Table 1.
Participant characteristics
| Diphenhydramine | Cetirizine | |
|---|---|---|
| n = 13 | n = 14 | |
| Gender (n (%) women) | 13 (100) | 13 (93) |
| Age (mean ± SD) | 59 ± 11 | 59 ± 8 |
| Weight in kg (mean ± SD) | 72.5 ± 22.7 | 71.5 ± 19.8 |
| Height in m (mean ± SD) | 1.61 ± 0.09 | 1.64 ± 0.08 |
| BMI (mean ± SD) | 27.8 ± 8.1 | 26.4 ± 6.3 |
| Ethnicity (n (%) Caucasians) | 12 (92) | 11 (79) |
| Degree of education (n (%) university) | 7 (54) | 7 (50) |
| Allergies (n (%)) a | 4 (31) | 6 (43) |
| Atopy (n (%)) b | 6 (46) | 2 (14) |
| Asthma and/or COPD (n (%)) | 2 (15) | 3 (21) |
| Menopause (n (%)) | 10 (77) | 11 (79) |
| ALT in U/l (mean ± SD) | 28 ± 29 | 28 ± 19 |
| AST in U/l (mean ± SD) | 31 ± 37 | 25 ± 13 |
| Total bilirubin in µmol/l (mean ± SD) | 7 ± 6 | 6 ± 3 |
| Creatinine clearance in ml/min (mean ± SD) | 76.1 ± 20.2 | 77.6 ± 18.9 |
| Type of cancer (n (%)) | ||
| Breast | 8 (61) | 10 (72) |
| Ovarian | 1 (8) | 1 (7) |
| Non-small cell lung cancer | 0 | 2 (14) |
| Endometrial | 2 (15) | 1 (7) |
| Thymus | 1 (8) | 0 |
| Vaginal | 1 (8) | 0 |
| Metastatic stage (n (%)) | 4 (31) | 2 (14) |
| Previous antineoplastic treatment (n (%)) | 6 (46) | 8 (57) |
| Dosing regimen (n (%)) | ||
| Every week | 8 (62) | 11 (79) |
| Every 3 weeks | 5 (38) | 3 (21) |
| Dose of paclitaxel (n (%)) | ||
| 45 mg/m2 | 0 | 1 (7) |
| 67 mg/m2 | 0 | 1 (7) |
| 80 mg/m2 | 8 (62) | 9 (64) |
| 175 mg/m2 | 5 (38) | 3 (22) |
| Other antineoplastic agents simultaneously (n (%)) | 8 (61) | 7 (50) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ALT, alanine transaminase; AST, aspartate transaminase
a Known hypersensitivity to a drug
b Allergic rhinitis and/or asthma and/or atopic dermatitis